0
July 1967, Vol 114, No. 1 >
Article | July 1967

The Treatment of Infants With Oxacillin Sodium FREE

Stuart H. Walker, MD; Willard E. Standiford, MD
[+] Author Affiliations

Received for publication Sept 27, 1966.

Reprint requests to Department of Pediatrics, Mercy Hospital, 301 St. Paul Place, Baltimore 21202 (Dr. Walker).


Am J Dis Child. 1967;114(1):64-68. doi:10.1001/archpedi.1967.02090220070012.
Text Size: A A A
Published online
Article
References
Comments

OXACILLIN SODIUM has been demonstrated to effectively inhibit penicillin-sensitive and resistant staphylococci in vitro at concentrations readily obtainable in vivo1 and together with other similar penicillinase-resistant penicillins, is considered a drug of choice in staphylococcal infection.2 As young infants are particularly susceptible to staphylococcal infection, information concerning the effectiveness of oxacillin sodium in treating such infections and the pharmacology of oxacillin sodium in such patients is needed. The study reported herein provides information regarding the serum concentrations of oxacillin sodium achieved with varying dosage schedules in young infants, the effectiveness of the drug in the treatment of severe staphylococcal infection in this age group, and the toxicity of the drug in newborns and in older infants.

Material and Methods  All patients less than 2 years of age admitted to the service wards or nurseries of the Department of Pediatrics, Mercy Hospital during the period July 1, 1963, to

REFERENCES

1 +
Gourevitch, A., et al:  Microbiological Evaluation of 5-methyl-3 Phenyl-4-Isoxazolyl Penicillin , Antibiot Chemother 11:780-789, 1961;.
2 +
White, A.C., and Smith, J.:  Antistaphylococcal Activity of Penicillin P-12: (5-Methyl-3-Phenyl-4-Isoxazolyl Penicillin) , Amer J Med Sci 243:202-208, 1962;.
3 +
Klein, J.O., et al:  Oxacillin Treatment of Severe Staphylococcal Infections , New Eng J Med 269:1216-1225, 1963;.
4 +
Abu-Nassar, H.; Williams, T.W.; and Yow, E.M.:  Comparative Laboratory and Clinical Observations on Two New Oral Penicillins, Oxacillin and Ancillin , Amer J Med Sci 245:459-466, 1963;.
5 +
Kirby, W.M.; Roxenfeld, L.S.; and Brodie, J.:  Oxacillin: Laboratory and Clinical Evaluation , JAMA 181:739-744, 1962;.
6 +
Walker, S.H.:  Colistin Therapy in Infants and Children , Amer J Dis Child 109:204-211, 1965;.
7 +
Bristol Laboratories: Basic Data on Penicillin P-12, Prostaphlin, Bristol Laboratories, 1963.
8 +
McCracken, G.H., and Eichenwald, H.F.:  Antimicrobial Therapy in Infancy and Childhood , Pediat Clin N Amer 13:231-250, 1966;.

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

1 +
Gourevitch, A., et al:  Microbiological Evaluation of 5-methyl-3 Phenyl-4-Isoxazolyl Penicillin , Antibiot Chemother 11:780-789, 1961;.
2 +
White, A.C., and Smith, J.:  Antistaphylococcal Activity of Penicillin P-12: (5-Methyl-3-Phenyl-4-Isoxazolyl Penicillin) , Amer J Med Sci 243:202-208, 1962;.
3 +
Klein, J.O., et al:  Oxacillin Treatment of Severe Staphylococcal Infections , New Eng J Med 269:1216-1225, 1963;.
4 +
Abu-Nassar, H.; Williams, T.W.; and Yow, E.M.:  Comparative Laboratory and Clinical Observations on Two New Oral Penicillins, Oxacillin and Ancillin , Amer J Med Sci 245:459-466, 1963;.
5 +
Kirby, W.M.; Roxenfeld, L.S.; and Brodie, J.:  Oxacillin: Laboratory and Clinical Evaluation , JAMA 181:739-744, 1962;.
6 +
Walker, S.H.:  Colistin Therapy in Infants and Children , Amer J Dis Child 109:204-211, 1965;.
7 +
Bristol Laboratories: Basic Data on Penicillin P-12, Prostaphlin, Bristol Laboratories, 1963.
8 +
McCracken, G.H., and Eichenwald, H.F.:  Antimicrobial Therapy in Infancy and Childhood , Pediat Clin N Amer 13:231-250, 1966;.

Correspondence

Submit a Letter
CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Clear Answers | Save For Later
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.
All you need to read in the other general journals
BMJ 2010;341:c5893-c1494.
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

© 2013 American Medical Association. All Rights Reserved.
Powered bySilverchair Information Systems